CRVS - Corvus

-

$undefined

N/A

(N/A)

Corvus NasdaqGM:CRVS Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the United States. The company's lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell atopic dermatitis, asthma, psoriasis, and fibrotic diseases. It also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer. It has a license agreement with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in South San Francisco, California.

Location: 901 Gateway Boulevard, South San Francisco, CA, 94080, United States | Website: https://www.corvuspharma.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

250M

Cash

44.21M

Avg Qtr Burn

-7.133M

Short % of Float

11.45%

Insider Ownership

3.80%

Institutional Own.

49.07%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Soquelitinib (CPI-818) Details
Cancer, Blood cancer, Peripheral T-cell Lymphomas

Phase 3

Data readout

Soquelitinib Details
Autoimmune Lymphoproliferative Syndrome

Phase 2

Data readout

Mupadolimab (CPI-006) Details
Cancer, Lung cancer, Renal cell carcinoma, Non-small cell lung carcinoma

Phase 2

Update

Soquelitinib (CPI-818) Details
Cancer, Renal cell carcinoma (renal cell cancer)

Phase 2

Initiation

Ciforadenant +/- ipilimumab and nivolumab Details
Cancer, 1L metastatic renal cell carcinoma (renal cell cancer)

Phase 1/2

Data readout

Mupadolimab + pembrolizumab Details
Cancer, Head and neck cancer, Non-small cell lung carcinoma

Phase 1

Data readout

Phase 1

Data readout

Failed

Discontinued